Last reviewed · How we verify
Hepatitis A Virus
Hepatitis A Virus vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protection against infection.
Hepatitis A Virus vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protection against infection. Used for Prevention of hepatitis A virus infection in children and adults.
At a glance
| Generic name | Hepatitis A Virus |
|---|---|
| Sponsor | Novartis |
| Drug class | Inactivated viral vaccine |
| Target | Hepatitis A Virus surface antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) hepatitis A virus particles that trigger both humoral and cellular immune responses. Upon exposure to the antigen, B cells produce specific antibodies (anti-HAV) that neutralize the virus and prevent infection. This provides long-term immunity, typically lasting decades or life.
Approved indications
- Prevention of hepatitis A virus infection in children and adults
Common side effects
- Injection site soreness or erythema
- Headache
- Fatigue
- Myalgia
- Low-grade fever
Key clinical trials
- A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) (PHASE3)
- A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection (PHASE2)
- DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (PHASE1)
- Study of Transfusion-Transmitted Infections
- ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention (NA)
- Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D
- People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents (PHASE4)
- Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study). (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hepatitis A Virus CI brief — competitive landscape report
- Hepatitis A Virus updates RSS · CI watch RSS
- Novartis portfolio CI